FLOVENT HFA
Total Payments
$85,720
Transactions
1
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $85,720 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $85,720 | 1 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Ph 2b, efficacy and safety study of ORal Bacterial EXtract ORBEX in children | GlaxoSmithKline, LLC. | $85,720 | 0 |
Top Doctors Receiving Payments for FLOVENT HFA
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Tucson, AZ | $85,720 | 1 |
Ad
Manufacturing Companies
- GlaxoSmithKline, LLC. $85,720
Product Information
- Type Drug
- Total Payments $85,720
- Total Doctors 0
- Transactions 1
About FLOVENT HFA
FLOVENT HFA is a drug associated with $85,720 in payments to 0 healthcare providers, recorded across 1 transactions in the CMS Open Payments database. The primary manufacturer is GlaxoSmithKline, LLC..
Payment data is available from 2017 to 2017. In 2017, $85,720 was paid across 1 transactions to 0 doctors.
The most common payment nature for FLOVENT HFA is "Unspecified" ($85,720, 100.0% of total).
FLOVENT HFA is associated with 1 research study, including "Ph 2b, efficacy and safety study of ORal Bacterial EXtract ORBEX in children" ($85,720).